Kambo

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: detox immunity pain

Research Overview

Overall, the research literature on Kambô (Kambo)—the skin secretion of the giant monkey/leaf frog Phyllomedusa bicolor used in ritual applications to superficial burns—has concentrated on (1) chemical and pharmacological characterization of its peptide mixture and (2) clinical descriptions of adverse events associated with contemporary use outside Indigenous contexts. The best-developed basic-science area is identification of constituent bioactive peptides (e.g., dermorphins/deltorphins and other vasoactive/neuroactive peptides) and mapping of plausible receptor targets (opioid, NK1, bradykinin, CRF/related pathways), which provides mechanistic plausibility for acute gastrointestinal, cardiovascular, endocrine, and neurologic effects. In parallel, the clinical literature is dominated by case reports/series describing toxicity patterns after rituals (often involving intentional overhydration), including prolonged vomiting, agitation/altered mental status, psychosis, severe electrolyte disturbances (notably hyponatremia), and rare catastrophic outcomes such as cerebral edema/brain death; at least one report also links use to Boerhaave syndrome, consistent with forceful emesis as a proximate mechanism.

The strongest evidence therefore supports Kambô’s capacity to produce acute, sometimes severe physiological disturbances rather than validated therapeutic benefit. Evidence for benefit is currently weakest and largely consists of self-reported outcomes from observational survey data, which suggest perceived improvements (including health-oriented behaviors and spiritual significance) but are highly susceptible to expectancy, selection, and setting effects and do not establish efficacy for any medical indication. A distinct but related evidence stream concerns dermorphin as an isolated compound: older clinical trial data (intrathecal dermorphin for postoperative pain) suggest potent analgesic activity compared with morphine/placebo, but this pertains to a purified peptide administered in a controlled medical route and context, not to whole-secretion Kambô rituals; moreover, this clinical line appears under-replicated and largely dormant.

Key research gaps include: rigorous epidemiology of adverse events (incidence, dose–response, and risk modifiers such as hydration practices, comorbidities, and co-exposures), standardized characterization of secretion composition and variability, and evidence-based clinical management algorithms for suspected toxicity (including hyponatremia/SIADH-like presentations and neurocritical complications). For claimed therapeutic effects of Kambô rituals, the field lacks controlled clinical studies with clear endpoints, safety monitoring, and attention to contextual/psychological confounders. Finally, translational work is needed to disentangle which specific peptides drive particular toxicities versus any putative benefits, and to evaluate whether any components (e.g., dermorphin) warrant renewed, ethically and clinically appropriate investigation as conventional pharmaceuticals rather than as unregulated ritual exposures.

1. What conditions has Kambo been studied for?

  • Postoperative pain (via dermorphin, not whole Kambo ritual): One abstract argues for re-exploring dermorphin—a peptide originally isolated from the skin of the Amazonian frog associated with “Kambo/Sapo”—for intrathecal analgesia in postoperative and palliative settings.

  • Palliative/terminal pain (proposed): The same dermorphin abstract proposes evaluation for palliative use in terminal patients (as a suggested future indication rather than established practice).

  • Chronic diseases of “mind and body” (claimed use; not established): One abstract describes Kambô as being used in emerging rituals to “heal chronic diseases of the mind and body,” but does not provide controlled clinical evidence for specific diagnoses.

  • Mental health outcomes (adverse events): Case-based literature in the abstracts includes psychosis potentially due to the kambô ritual.

  • Toxicology/acute medical emergencies: Multiple abstracts focus on serious acute outcomes after Kambo use, including prolonged vomiting and altered mental status, severe hyponatremia with cerebral edema leading to brain death, and Boerhaave syndrome (esophageal rupture) after use.

  • User-reported “wellness” motivations: An online survey abstract investigated motivations, ritual settings, and subjective experiences (not a disease-specific clinical trial).

2. Does it work in treating those conditions? Summarize the evidence.

  • Postoperative pain (dermorphin, intrathecal): The dermorphin abstract reports that a randomized, placebo-controlled postoperative pain study (reported in 1985) found intrathecal dermorphin “impressively superior” to placebo and morphine. However, the abstract also emphasizes that this study was rarely cited, did not lead to broader clinical adoption, and calls for new clinical studies—suggesting the evidence base is limited/underdeveloped and not recently replicated (at least as represented in these abstracts).

  • General healing / chronic mind-body diseases (whole Kambo ritual): The provided abstracts do not include controlled clinical trials demonstrating efficacy of the Kambo ritual for specific chronic diseases. The survey reports that many users claimed beneficial effects, but this is self-report and the authors note effects may be influenced by setting and expectations.

  • Mental health: Rather than evidence of benefit, the abstracts include a case study of psychosis potentially due to the kambô ritual, which supports potential harm rather than therapeutic efficacy.

Overall, within these abstracts, the strongest “treatment” evidence is for a single older clinical trial of intrathecal dermorphin (a specific peptide), not for the unregulated Kambo ritual as practiced.

3. What health benefits does it have?

  • User-reported benefits (survey data): In the online survey, the majority of users claimed beneficial effects, including “more health-orientated behaviors,” and many assigned Kambô high personal and spiritual significance. The authors caution that expectation/setting may modulate reported effects.

  • Potential analgesic benefit (specific peptide, clinical context): Dermorphin—isolated from frog skin associated with Kambo—was described as more selective and potent than morphine in animal models after intracerebroventricular administration, and superior to placebo and morphine in an older postoperative pain trial when given intrathecally (per the abstract). This is a potential benefit of a purified compound under medical administration, not evidence that the ritual itself is a safe or effective analgesic.

These abstracts do not provide robust clinical evidence that the Kambo ritual produces durable medical benefits for specific diseases; benefits described are largely subjective or relate to isolated peptides studied in medical contexts.

4. Does it have any downsides or side effects?

  • Severe, potentially fatal hyponatremia and brain death: One abstract presents the first documented case of brain death associated with Kambô toxicity, describing a “perfect storm” of extreme emesis, excessive water intake, and suspected SIADH/ADH dysregulation leading to severe hyponatremia, diffuse cerebral edema, and loss of intracranial blood flow.

  • Prolonged vomiting and neurobehavioral symptoms: A case report describes a patient presenting ~22 hours after a Kambo cleanse with prolonged vomiting, flushing, facial swelling, altered mental status, and agitation requiring chemical restraints, along with characteristic small circular burns at the application site.

  • Psychiatric adverse event: One case study reports psychosis potentially due to the kambô ritual.

  • Boerhaave syndrome (esophageal rupture): One abstract describes Boerhaave syndrome in an otherwise healthy male after Kambo use—consistent with the risk that forceful vomiting/retching can cause serious gastrointestinal injury.

  • Predictable acute physiologic distress from peptides: The mechanistic abstract notes Kambo secretions contain multiple bioactive peptides (e.g., phyllocaerulein, phyllomedusin, phyllokinin, sauvagine, dermorphins, deltorphins) acting on CCK, NK1, bradykinin B2, CRF, and opioid receptors, producing profound disturbances such as violent emesis, vasodilation, fluid shifts, and endocrine effects.

  • Local injury from administration method: The ritual involves application to fresh superficial burns; case descriptions note “dot-like” burn patterns and superficial burn wounds used for resin introduction.

Across the abstracts, the downsides range from expected acute toxicity (vomiting, flushing) to rare but catastrophic outcomes (hyponatremia with cerebral edema/brain death, esophageal rupture) and psychiatric complications.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic analyses or specific gene–response relationships for Kambo or its peptides.

  • No direct evidence in these abstracts: There are no data here linking genetic variants (e.g., opioid receptor genes, vasopressin pathway genes, peptide metabolism genes) to either benefit or harm from Kambo.

  • Mechanistic plausibility but unproven: Because Kambo peptides interact with opioid receptors (μ, δ) and may contribute to ADH/SIADH-related hyponatremia, genetic variation in these pathways could theoretically influence response or risk, but this is speculative based on the abstracts provided and not evidence-based here.

References

  1. Boerhaave syndrome following the use of Kambo from the Amazonian
    Christopher R Darlington, Nicolas Copertino (2023) - Oxford medical case reports
  2. Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation.
    Jan M Keppel Hesselink, Michael E Schatman (2018) - Journal of pain research
  3. Connected to the spirit of the frog: An Internet-based survey on Kambô, the secretion of the Amazonian Giant Maki Frog (
    Tomislav Majić, Meike Sauter, Felix Bermpohl, Timo T Schmidt (2021) - Journal of psychopharmacology (Oxford, England)
  4. The Amazonian kambô frogPhyllomedusa bicolor(Amphibia: Phyllomedusidae): Current knowledge on biology, phylogeography, toxinology, ethnopharmacology and medical aspects
    Thais A C Nogueira, Igor Luis Kaefer, Marco A Sartim, Manuela B Pucca, Jacqueline Sachett (2022)
  5. Prolonged toxicity from Kambo cleansing ritual
    Kai Li, Howard Horng, Kara Lynch, Craig G Smollin (2018)
  6. Can Overuse of Kambô Cause Psychosis?
    Renitha Roy, Aparna Baranwal, Eduardo D Espiridion (2018) - Cureus
  7. KAMBÔ: an Amazonian enigma.
    Vidal Haddad Junior, Itamar Alves Martins (2020) - Journal of venom research
  8. Unusual Unsatisfactory Treatment in Two Patients with Imported Cutaneous Leishmaniasis.
    Anna Kuna, Romuald Olszański, Beata Szostakowska, Natalia Kulawiak, Ravi Kant, Maciej Grzybek (2024) - Tropical medicine and infectious disease
  9. Shamanic Kambô Frog Hyponatremic Toxicity Leading to Brain Death: A Case Report.
    Christina Q Tran, Rebecca Houston, Maxwell A Marino, Michael Schiraldi, Dan E Miulli (2025) - Cureus
  10. Kambo Administration and Its Association With Sudden Death: Clinical and Forensic Perspectives From a Systematic Review.
    Matteo Antonio Sacco, Saverio Gualtieri, Chara Spiliopoulou, Emmanouil I Sakelliadis, Maria Cristina Verrina, Isabella Aquila (2025) - Cureus


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!